Fluoxetine delays the cognitive function decline and synaptic changes in a transgenic mouse model of early Alzheimer's disease
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder associated with cognitive decline. Previous studies have reported that the syndrome of AD begins with subtle alterations in hippocampal synapses prior to frank neuronal degeneration. It has recently been reported that fluoxetine (FLX) shows positive effects on AD patients who have depression and anxiety. However, it is unclear whether FLX can affect the pathogenesis of AD mice in the early stage of AD. To address this question, 8‐month‐old male APP/PS1 double‐transgenic AD mice were administered a 10‐week course of FLX (10 mg/kg/day) injections. Then, spatial learning and memory were evaluated using a Morris water maze test. Immunohistological staining and an unbiased stereological method were used to estimate the total number of dendritic spine synapses in the hippocampus. We found that FLX significantly shortened the mean escape latencies of the 10‐month‐old mice; reduced the elevated levels of soluble Aβ40, Aβ42, and amyloid plaques in the hippocampus; and prevented the decrease in dendritic spine synapses and in postsynaptic protein PSD‐95 density in the dentate gyrus, CA1/2 and CA3 regions of the hippocampus. Our results indicate that reversing synaptic impairment might be considered a promising therapeutic approach for alleviating the cognitive deficits associated with early AD. Moreover, our results suggest that FLX may be a safe and effective drug for delaying the progress of AD, which might provide a starting point for further research into new preventative measures and treatments for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376
2018 Alzheimer's disease facts and figures
Alzheimer's Association (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.001 · Cited by 1,912
A learning deficit related to age and β-amyloid plaques in a mouse model of Alzheimer's disease
Chen, G., Chen, K. S., Knox, J., Inglis, J., Bernard, A., Martin, S. J., Justice, A., McConlogue, L., Games, D., Freedman, S. B., et al. (2000) · Nature · doi:10.1038/35050103 · Cited by 740
Lee, S. J. C., Nam, E., Lee, H. J., Savelieff, M. G., & Lim, M. H. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00731g · Cited by 576
Effect of Citalopram on Agitation in Alzheimer Disease: The CitAD Randomized Clinical Trial
Porsteinsson, A. P., Drye, L. T., Pollock, B. G., Devanand, D. P., Frangakis, C., Ismail, Z., Marano, C., Meinert, C. L., Mintzer, J. E., Munro, C. A., et al. (2014) · JAMA · doi:10.1001/jama.2014.93 · Cited by 572 · cited 1×
“…in Alzheimer's dementia, finding either favorable effects (Mokhber et al., 2014; Mowla, Mosavinasab, & Pani, 2007), no effects (Choe et al., 2016; Lyketsos et al., 2003; Munro et al., 2012), or even disadvantageous effects of SSRI treatment (Banerjee et al., 2011; Porsteinsson et al., 2014).”
BackgroundBanerjee, S., Hellier, J., Dewey, M., Romeo, R., Ballard, C., Baldwin, R., Bentham, P., Fox, C., Holmes, C., Katona, C., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60830-1 · Cited by 532 · cited 2×
“…in Alzheimer's dementia, finding either favorable effects (Mokhber et al., 2014; Mowla, Mosavinasab, & Pani, 2007), no effects (Choe et al., 2016; Lyketsos et al., 2003; Munro et al., 2012), or even disadvantageous effects of SSRI treatment (Banerjee et al., 2011; Porsteinsson et al., 2014).”
BackgroundCheng, D., Hoogenraad, C. C., Rush, J., Ramm, E., Schlager, M. A., Duong, D. M., Xu, P., Wijayawardana, S. R., Hanfelt, J., Nakagawa, T., et al. (2006) · Molecular & Cellular Proteomics · doi:10.1074/mcp.d500009-mcp200 · Cited by 510
Depressive symptoms and risk of dementia: The Framingham Heart Study
Saczynski, J. S., Beiser, A., Seshadri, S., Auerbach, S., Wolf, P. A., & Au, R. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e62138 · Cited by 488 · cited 1×
“Late-life depression is associated with an increased risk of Alzheimer's dementia (Barnes et al., 2012; Diniz, Butters, Albert, Dew, & Reynolds 3rd., 2013; Dotson, Beydoun, & Zonderman, 2010; Mourao, Mansur, Malloy-Diniz, Castro Costa, & Diniz, 2016; Saczynski et al., 2010).”
Hippocampal volume, memory, and cortisol status in major depressive disorder: Effects of treatment
Vythilingam, M., Vermetten, E., Anderson, G. M., Luckenbaugh, D., Anderson, E. R., Snow, J., Staib, L. H., Charney, D. S., & Bremner, J. D. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.04.002 · Cited by 477
Lyketsos, C. G., DelCampo, L., Steinberg, M., Miles, Q., Steele, C. D., Munro, C., Baker, A. S., Sheppard, J.-M. E., Frangakis, C., Brandt, J., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.7.737 · Cited by 398
Synaptic pathology in Alzheimer's disease: a review of ultrastructural studies
Scheff, S. (2003) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.08.002 · Cited by 391
Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment
Dotson, V. M., Beydoun, M. A., & Zonderman, A. B. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e62124 · Cited by 385
Cirrito, J. R., Disabato, B. M., Restivo, J. L., Verges, D. K., Goebel, W. D., Sathyan, A., Hayreh, D., D'Angelo, G., Benzinger, T., Yoon, H., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1107411108 · Cited by 377
Alzheimer’s disease-related alterations in synaptic density: neocortex and hippocampus.
Scheff, S. W., & Price, D. A. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-9s312 · Cited by 284
Garcia-Alloza, M., Gil-Bea, F. J., Diez-Ariza, M., Chen, C. P. L.-H., Francis, P. T., Lasheras, B., & Ramirez, M. J. (2005) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2004.06.007 · Cited by 244 · cited 1×
“Garcia-Alloza et al. found a marked depletion in the levels of serotonin (5-HT) and its metabolite 5-hydroxyindoleacetic acid (5-HIAA) in both the frontal and temporal cortices from AD patients (Garcia-Alloza et al., 2005).”
BackgroundShao, C. Y., Mirra, S. S., Sait, H. B. R., Sacktor, T. C., & Sigurdsson, E. M. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0843-x · Cited by 219
Bartels, C., Wagner, M., Wolfsgruber, S., Ehrenreich, H., Schneider, A., & Initiative, F. T. A. D. N. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17040404 · Cited by 202
Mowla, A., Mosavinasab, M., Haghshenas, H., & Haghighi, A. B. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31814b98c1 · Cited by 116
Shen, F., Smith, J. A. M., Chang, R., Bourdet, D. L., Tsuruda, P. R., Obedencio, G. P., & Beattie, D. T. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.02.026 · Cited by 79
Choe, Y. M., Kim, K. W., Jhoo, J. H., Ryu, S. H., Seo, E. H., Sohn, B. K., Byun, M. S., Bak, J., Lee, J., Yun, H. J., et al. (2016) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4384 · Cited by 31
Cited by
Microglia, Lifestyle Stress, and Neurodegeneration
Madore, C., Yin, Z., Leibowitz, J., & Butovsky, O. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.003 · Cited by 311
Diagnosing and Treating Depression in Patients with Alzheimer’s Disease
Burke, A. D., Goldfarb, D., Bollam, P., & Khokher, S. (2019) · Neurology and Therapy · doi:10.1007/s40120-019-00148-5 · Cited by 115
Glucocorticoids, synaptic plasticity and Alzheimer’s disease
Klyubin, I., Ondrejcak, T., Hu, N.-W., & Rowan, M. J. (2022) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2022.100365 · Cited by 16
Qin, M., Wu, J., Zhou, Q., Liang, Z., & Su, Y. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.09.039 · Cited by 12
Metadata
- Authors
- Zhou, C., Chao, F., Zhang, Y., Jiang, L., Zhang, L., Fan, J., Wu, Y., Dou, X., & Tang, Y.
- Venue
- Journal of Comparative Neurology
- Publisher
- Wiley
- Published
- 2019-01-25
- Volume
- 527
- Issue
- 8
- Pages
- 1378-1387
- ISSN
- 0021-9967 (ISSN-L)
- 1096-9861
- OpenAlex
- W2907162195
- Cited by
- 44
- References
- 20
- FWCI
- 2.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.